212 related articles for article (PubMed ID: 32459817)
21. Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Milling RV; Grimm D; Krüger M; Grosse J; Kopp S; Bauer J; Infanger M; Wehland M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347815
[TBL] [Abstract][Full Text] [Related]
22. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
[TBL] [Abstract][Full Text] [Related]
23. Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.
Zago E; Galluzzo A; Pradella S; Antonuzzo L; Maggi M; Petrone L; Sparano C
Endocrine; 2024 Jan; 83(1):26-40. PubMed ID: 37851242
[TBL] [Abstract][Full Text] [Related]
24. Cabozantinib for the treatment of advanced medullary thyroid cancer.
Nagilla M; Brown RL; Cohen EE
Adv Ther; 2012 Nov; 29(11):925-34. PubMed ID: 23104465
[TBL] [Abstract][Full Text] [Related]
25. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
[TBL] [Abstract][Full Text] [Related]
26. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.
Saltiki K; Simeakis G; Karapanou O; Paschou SA; Alevizaki M
Endocrine; 2023 Jun; 80(3):570-579. PubMed ID: 36626081
[TBL] [Abstract][Full Text] [Related]
27. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
[TBL] [Abstract][Full Text] [Related]
28. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
29. Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.
Ahn HY; Chae JE; Moon H; Noh J; Park YJ; Kim SG
Endocrinol Metab (Seoul); 2020 Dec; 35(4):811-819. PubMed ID: 33212545
[TBL] [Abstract][Full Text] [Related]
30. cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
Prescrire Int; 2016 Jan; 25(167):11-3. PubMed ID: 26942253
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
[TBL] [Abstract][Full Text] [Related]
32. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.
Højer Wang L; Wehland M; Wise PM; Infanger M; Grimm D; Kreissl MC
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768635
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
[TBL] [Abstract][Full Text] [Related]
34. [Medullary thyroid carcinoma: current clinical progress].
Kroiss M; Koehler VF; Spitzweg C
Dtsch Med Wochenschr; 2021 Nov; 146(23):1527-1532. PubMed ID: 34826838
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Lassalle S; Zangari J; Popa A; Ilie M; Hofman V; Long E; Patey M; Tissier F; Belléannée G; Trouette H; Catargi B; Peyrottes I; Sadoul JL; Bordone O; Bonnetaud C; Butori C; Bozec A; Guevara N; Santini J; Hénaoui IS; Lemaire G; Blanck O; Vielh P; Barbry P; Mari B; Brest P; Hofman P
Oncotarget; 2016 May; 7(21):30461-78. PubMed ID: 27036030
[TBL] [Abstract][Full Text] [Related]
36. Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib.
Ackerman J; Kent S; Walker P
Ann Otol Rhinol Laryngol; 2020 Jul; 129(7):657-661. PubMed ID: 32037846
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
38. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
39. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.
Cabanillas ME; Hu MI; Jimenez C
J Clin Endocrinol Metab; 2014 Dec; 99(12):4390-6. PubMed ID: 25238206
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
